Summary

Feasibility Assessment: Is There Enough Evidence to Support This Meta-Analysis?

Studies Found - Mapped to Your PICO

Tier 1 - Direct HbA1c + colorectal surgery studies (eligible or partially eligible)

Tier 2 - CRC studies measuring diabetes/hyperglycemia + AL (HbA1c may be extractable)

Tier 3 - The 12 primary studies inside Wong et al. 2022 (all abdominal surgery, but some are colorectal)

The Critical Feasibility Issue: HbA1c vs. "Diabetes" Distinction

• Studies measuring HbA1c directly in CRC/colorectal surgery + reporting AL: probably 4-8 studies worldwide (Gustafsson 2009 is the oldest; Gagnon-Choy 2026 is the newest and largest)
• Studies measuring diabetes status + AL in CRC: dozens (but these are a different PICO and cannot be pooled with HbA1c studies)

Realistic Study Count Estimate

Key Risks to the Proposal

1. HbA1c threshold heterogeneity. Studies use different cut-offs: >6.0%, >6.5%, >7.0%, >8.0%. Meta-regression and subgroup analyses will be needed (as Wong et al. 2022 did), which requires a minimum of ~8-10 studies to be statistically credible.
2. AL definition inconsistency. Studies use different AL definitions (ISREC grade A/B/C vs. clinical vs. radiological). This will be a major source of heterogeneity.
3. Small AL event counts. Even large cohort studies (e.g. Gustafsson: 120 patients, only 2 AL events) are severely underpowered for AL specifically. This is why most studies report HbA1c against "any complication" rather than AL specifically.
4. Gagnon-Choy 2026 (PMID 42084129) - this is the most important new paper. It uses NSQIP data on 32,578 elective colorectal patients and measures HbA1c, but the abstract does not isolate anastomotic leakage as a standalone outcome. If AL data is present in the dataset (NSQIP does record it), contacting the authors or using the NSQIP database directly could be a major addition.
5. The 2023 He et al. meta-analysis (PMID 37386211) used "diabetes" (not HbA1c) as the exposure for AL risk - its 16 primary studies cannot be directly included in your HbA1c-specific review, but the primary datasets may overlap and contain HbA1c data.

Recommendation

1. Proceed with PROSPERO registration - the gap is real and confirmed.
2. Pre-specify a dual analytic strategy: (a) primary meta-analysis if ≥5 eligible HbA1c + AL studies found; (b) systematic narrative review if insufficient studies for pooling. State this upfront in your protocol.
3. Broaden your search slightly to include studies reporting HbA1c + any colorectal surgery complication where AL data can be extracted from tables - even if AL was not the authors' primary outcome.
4. Contact Gagnon-Choy et al. (2026) for NSQIP AL sub-data - a 32,578-patient dataset with HbA1c stratification would be a powerful anchor study.
5. Include the 12 Wong et al. 2022 primary studies as a seeded reference list for your full-text screening - some will be CRC-specific and HbA1c-measured.
6. Consider a GRADE assessment note in your protocol: if fewer than 5 studies are ultimately eligible, the review will shift from a quantitative synthesis to a descriptive systematic review, per PRISMA 2020 guidance.

7-Dimension Scorecard: Hypoalbuminemia + AL (vs. HbA1c + AL as reference)

1. Data Availability ✅✅✅ STRONG (vs. HbA1c: ⚠️ Borderline)

2. Exposure Definition ✅✅ SOLID (vs. HbA1c: ⚠️ Problematic)

• Standardization: Serum albumin is measured by bromocresol green/purple assay in virtually all labs worldwide - highly reproducible. HbA1c by contrast has multiple assay methods and is susceptible to haemoglobin variants.
• Threshold variability: This is the key challenge. Studies use 3.0, 3.5, and 4.0 g/dL as cut-offs, sometimes without clinical justification. The dose-response design you are proposing directly addresses this - it is the methodologically correct response to threshold heterogeneity.
• Confounding: Albumin reflects more than just nutrition (also inflammation via acute phase response, liver function, capillary permeability). This is both a limitation and a justification: unpacking the albumin-AL relationship at different thresholds adds mechanistic insight.
• Timing: Most studies measure albumin within 1-2 weeks preoperatively. Choi et al. (2023) specifically tested within 1 week of surgery - timing is usually well-reported.

3. Methodological Simplicity ✅✅✅ HIGH (vs. HbA1c: ⚠️ Complex)

4. Competition Gap ✅✅ REAL BUT REQUIRES PRECISE FRAMING (vs. HbA1c: ✅✅✅ Clear)

• Wang et al. 2019 (PMID 30660450): Published as a letter/meta-analysis in Asian J Surg - perioperative albumin monitoring in CRC patients predicting AL. Small, narrow, possibly pooling only post-op albumin data.
• Elfadil et al. 2026 (PMID 41913878): PROSPERO-registered systematic review (32 studies) on nutritional status + AL in colorectal surgery - published February 2026. This is the most important competitor. However: it covers all nutritional markers (BMI, SGA, NRI, PNI, albumin combined), did not perform a standalone albumin meta-analysis, and did not perform dose-response analysis stratified by albumin threshold.
• He et al. 2023 colon cancer meta-analysis (PMID 37386211): Covers multiple risk factors including albumin/nutrition but does not isolate albumin with dose-response.

5. Heterogeneity Expected ⚠️ MODERATE-HIGH (vs. HbA1c: ⚠️ High)

• Population mix: Colon vs. rectal (different AL rates: ~2-4% colon vs. 8-15% rectal), cancer vs. benign, elective vs. emergency - studies include different mixes
• ERAS effect: The Choi 2023 study actually found null association with albumin in an ERAS setting, suggesting ERAS protocols may attenuate the albumin-AL relationship. If you pool ERAS and non-ERAS studies, I² will be high
• Albumin threshold variation: 3.0, 3.5, 4.0 g/dL used across studies - this is exactly why dose-response is the right method, but also why pooling categorical data will be heterogeneous
• AL definition: Clinical (symptomatic) vs. radiological vs. any-grade AL varies widely

6. Clinical Impact ✅✅✅ HIGH (vs. HbA1c: ✅✅ Moderate)

• Albumin is directly modifiable preoperatively: nutritional prehabilitation, oral nutritional supplements, enteral/parenteral nutrition, albumin infusion, ERAS immunonutrition protocols
• A clearly defined albumin threshold for AL risk would directly inform surgical postponement decisions and prehabilitation thresholds - something currently handled inconsistently (different units use 3.0 vs. 3.5 vs. 4.0 g/dL)
• The finding from Choi 2023 that ERAS nullifies the albumin-AL association has enormous implications if confirmed: it suggests correction of hypoalbuminemia via ERAS nutritional protocols may be protective
• Surgeons, anaesthetists, dietitians, and oncology MDTs all act on albumin data preoperatively
• AL carries 5-18% mortality; any modifiable predictor with a dose-response relationship is immediately clinically translatable

7. Student Feasibility ✅✅✅ HIGH (vs. HbA1c: ⚠️ Difficult)

Overall Comparison Table

Recommendation

7-Dimension Scorecard: ctDNA Proposal vs. All Three Topics

1. Data Availability

• The 2026 CRLM meta-analysis (PMID 41723037, 10 studies, 1,034 patients) explicitly found: "Preoperative ctDNA was not a statistically significant predictor" of recurrence - while postoperative ctDNA was strongly predictive (HR 3.28-8.69)
• The 2023 Faulkner meta-analysis (PMID 36347967) included 37 studies but specifically measured ctDNA after curative surgery
• Chen et al. 2022 (PMID 35384496) pooled 8 studies of postoperative ctDNA (HR 5.41)

2. Exposure Definition

3. Methodological Simplicity

4. Competition Gap

5. Heterogeneity Expected

1. Assay platform (tumor-informed vs. tumor-naive, ddPCR vs. NGS vs. methylation) - this alone creates irreconcilable I² values
2. Timing of "preoperative" sample - day of surgery? 1 week prior? During staging workup? Varies widely
3. Stage mix - a stage I patient's ctDNA positive rate may be 5-10%; stage III may be 60-80% - pooling these without perfect stage stratification creates massive heterogeneity
4. Adjuvant chemotherapy - patients who went on to receive adjuvant chemotherapy will have different recurrence trajectories than those who didn't, confounding the ctDNA-recurrence relationship
5. Definition of "early recurrence" - 6 months? 12 months? 24 months? 5-year DFS? Every study uses a different endpoint
6. CRC site - right colon, left colon, rectum all have different molecular profiles and mutational landscapes affecting ctDNA shedding

6. Clinical Impact

• ctDNA-guided adjuvant therapy is already entering clinical practice (DYNAMIC, GALAXY, CIRCULATE programs) with RCT evidence
• A meta-analysis confirming preoperative ctDNA positivity predicts early recurrence by stage would directly inform who needs more aggressive adjuvant treatment upfront and which stage II patients truly need chemotherapy (the most contested area in CRC management)
• NCCN and ESMO are actively evaluating ctDNA for adjuvant therapy decisions - a preoperative ctDNA meta-analysis would feed directly into guideline revision
• The clinical stakes are very high: stage II CRC, 20-30% recurrence rate, adjuvant chemotherapy controversial - ctDNA-positive patients could be identified preoperatively for treatment intensification
• However: this also means the field is moving so fast that a student meta-analysis may be superseded by DYNAMIC-III or CIRCULATE-Japan final results before publication

7. Student Feasibility

Full 3-Way Comparison Table

Final Ranking with Rationale

The ctDNA Proposal's Fatal Flaw in One Sentence

Genuine, Specific Meta-Analysis Gaps in Colorectal Oncosurgery (2026)

🥇 GAP 1 - THE STRONGEST

Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictor of Anastomotic Leakage After Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis With Threshold Analysis

🥈 GAP 2

Preoperative Serum Albumin and Anastomotic Leakage After Colorectal Cancer Surgery: A Dose-Response Meta-Analysis Stratified by Albumin Threshold

🥉 GAP 3

Preoperative C-Reactive Protein-to-Albumin Ratio (CAR) and Risk of Anastomotic Leakage After Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis

• Yu et al. 2020: preoperative CAR predicts AL in elderly patients post-curative colorectal surgery
• Multiple nomogram studies in rectal cancer include CAR as an independent variable
• CRP meta-analyses (CRP as postoperative predictor) exist but do not examine preoperative CAR
• Albumin meta-analyses do not incorporate the ratio form

GAP 4

Impact of Preoperative Frailty on Postoperative Morbidity, Anastomotic Leakage, and 30-Day Mortality After Elective Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis

• Frailty meta-analysis exists for liver resection (PMID 38856830, 2024) and general surgery broadly
• No dedicated meta-analysis exists for colorectal cancer surgery specifically
• Frailty is measured by multiple validated tools (CFS, mFI-5, mFI-11, FRAIL scale, PRISMA-7) - subgroup by tool is a planned source of heterogeneity
• Clinically extremely relevant: aging CRC population, fitness for surgery decisions, prehabilitation programs

GAP 5

Preoperative Prognostic Nutritional Index (PNI) and Anastomotic Leakage After Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis

• PNI (= 10 × albumin [g/dL] + 0.005 × total lymphocyte count) has been validated in dozens of CRC surgery cohort studies as an independent predictor of AL
• A meta-analysis on PNI and overall survival/recurrence in CRC exists
• No meta-analysis on PNI specifically and anastomotic leakage as primary outcome exists
• Wang et al. 2024 multicenter study (n=577) found PNI independently predicts AL (p<0.05)
• Wu et al. 2025 rectal cancer study (n=434) found PNI (OPNI) OR=0.705 for AL

Final Recommendation Table

The Single Best Recommendation

Is Postoperative CAR a Genuine Research Gap? Full Analysis.

What Currently Exists: The CRP/Albumin Landscape

Existing meta-analyses - what they DO and DO NOT cover

Primary Study Evidence: What Exists for Pooling

The Precise Gap Statement

"Multiple meta-analyses have established postoperative CRP alone as an AL predictor (AUC ~0.80-0.87, POD 3-5). However, CRP has two fundamental limitations: (1) it does not account for the confounding effect of baseline albumin level on CRP magnitude, and (2) it has low positive predictive value (21-30%), generating high false-positive rates. The CRP/albumin ratio (CAR) addresses both limitations simultaneously - it normalizes the inflammatory signal against the patient's nutritional reserve, mechanistically linking the two main pathophysiological drivers of AL (systemic inflammation and impaired healing). Three published cohort studies (n=1,183 to n=72) report CAR consistently outperforming CRP alone at POD 3-5, with AUCs of 0.825-0.986. No systematic review or meta-analysis has pooled postoperative CAR data across studies, and no optimal cut-off has been established."

The 7-Dimension Scorecard for Postoperative CAR + AL

1. Data Availability ⚠️ BORDERLINE - The Key Weakness

• Confirmed eligible studies: 3-4 (Paliogiannis 2021, CARPAL 2025, Research Square preprint 2025, Yu 2020 partially)
• Potentially eligible (CRP + albumin measured separately; CAR calculable from raw data): another 5-10 studies within the large CRP meta-analyses
• The crucial point: the Bona 2023 meta-analysis (25 studies, 11,144 patients) included studies that measured both CRP and albumin postoperatively. If their primary authors or supplementary data includes albumin values, CAR could be re-extracted from those datasets

2. Exposure Definition ✅✅✅ EXCELLENT

• Paliogiannis: postoperative albumin (measured same day as CRP, POD 4)
• Research Square preprint: preoperative albumin as denominator (CRP postoperative ÷ preoperative albumin)
• CARPAL: both preoperative and POD 3 albumin

3. Methodological Simplicity ✅✅ GOOD

• Diagnostic accuracy meta-analysis (sensitivity, specificity, AUC pooling using HSROC/bivariate model)
• This is slightly more complex than a standard OR-based meta-analysis - requires the bivariate random effects model (STATA midas package or R mada/reitsma)
• The postoperative day subgroup analysis (POD 3 vs 4 vs 5) is pre-specified and methodologically clean
• The albumin source subgroup (pre-op vs post-op albumin) adds a second planned subgroup

4. Competition Gap ✅✅✅ CONFIRMED EMPTY

• Bona 2023 (CRP + PCT alone, no CAR)
• McKechnie 2024 (preoperative CRP only)
• The inflammatory biomarkers SR (individual biomarkers, explicitly notes "combination of biomarkers could increase predictive accuracy but data meta-regression was not possible")

5. Heterogeneity Expected ⚠️ MODERATE

• POD of measurement (3, 4, 5 - major source; addressed by subgroup)
• Albumin in denominator: pre-op vs post-op (addressed by subgroup)
• Colorectal cancer only vs mixed colorectal surgery - manageable
• AL definition (clinical vs radiological vs any grade)
• Open vs laparoscopic (CARPAL was 91% laparoscopic; Research Square was all open)

6. Clinical Impact ✅✅✅ HIGH

• The McKechnie 2024 meta-analysis found preoperative CRP is not a significant predictor of AL - meaning surgeons currently have no reliable preoperative biomarker. Postoperative CAR at POD 3-5 fills that void
• If CAR outperforms CRP alone (as all three primary studies suggest), it changes the daily blood test protocol: instead of checking CRP only, surgeons check CRP and albumin and calculate the ratio
• Both tests are already done routinely postoperatively in most units - the clinical cost of implementing CAR is essentially zero
• CAR at POD 3 with AUC 0.825-0.986 allows safe early discharge of low-risk patients and early re-operation or CT investigation of high-risk patients - directly reducing delayed diagnosis (mean diagnosis currently at 6.9-7.7 days postoperatively)
• The CARPAL study specifically shows that albumin alone is not significant (p not significant) while CAR is significant (p<0.001) - this is the key finding that justifies the ratio over either component alone

7. Student Feasibility ✅✅ GOOD (with one caveat)

Overall Verdict

The Single Most Important Recommendation

Full Assessment: TaTME vs Laparoscopic TME - Long-term Functional and Oncologic Outcomes as a Meta-Analysis Topic

The Existing Meta-Analysis Graveyard

What the Existing Meta-Analyses Have Concluded

On long-term oncologic outcomes:

• Moon 2022 (11 studies, 2,143 pts): No significant difference in OS, DFS, local recurrence, or distant recurrence between TaTME and transabdominal TME. I² for local recurrence = 66% (high heterogeneity).
• EAES/ESCP/ESGAR 2026: 34 fewer disease recurrences at 2 years per 1,000 patients with TaTME vs LaTME (95% CI 53 fewer to 11 fewer) - statistically significant.
• Zhao 2025 (matched cohorts, 6,970 pts): Comparable oncological outcomes except lower CRM positivity with TaTME.

On functional outcomes:

• Choy 2021 (7 studies, 475 pts): No significant difference in LARS scores (30.6 vs 28.3), IPSS, or EORTC QoL.
• Lauricella 2024 (11 studies, 1,020 pts): No significant difference in LARS (MD 2.81, p=0.3; I²=97%), Jorge-Wexner, EORTC, or IPSS.
• Geitenbeek 2024 (4-way MA, 2,495 pts): No significant differences across TME techniques for urinary/sexual/fecal function except R-TME vs L-TME urinary function at 3 months.

The RCT Anchor - COLOR III (2026):

• International phase 3 RCT, 28 hospitals globally
• TaTME vs LapTME for (y)cT1-3N0-2M0 rectal cancer ≤10 cm from anal verge
• Short-term (90-day) results: Similar major morbidity, similar anastomotic leak rates, similar complete resection. TaTME significantly lower conversion rate.
• Long-term follow-up pending - this is the critical missing data point

The 7-Dimension Score: As Broadly Framed

Where Genuine Sub-Gaps Actually Exist Within This Topic

Sub-gap A - Most Promising ✅✅✅

• Moon 2022 meta-analysis used studies with variable follow-up, many <2 years. Mean follow-up across included studies was ~24 months.
• EAES/ESCP 2026 MA reported "disease recurrence at 2 years" - not 3 or 5 years.
• The COLOR III RCT (Lancet GE, 2026) has only short-term data published; long-term results are explicitly "pending."
• Local recurrence in rectal cancer commonly occurs up to 5 years post-surgery. A 2-year endpoint misses 30-40% of recurrences.
• Since Moon 2022, multiple new cohort studies with ≥3-year follow-up have been published (Frontiers Oncol 2026, Denmark multicenter 2023, Gloor 2023, etc.)

Sub-gap B - Solid ✅✅

• Every existing MA mixes all BMI groups
• TaTME's proposed advantage is specifically in difficult pelvises - obesity, narrow pelvis, high BMI
• Zewde et al. 2026 (Dis Colon Rectum, PMID 41378993) just published a multicenter TaTME obesity study
• If TaTME's benefit is concentrated in BMI ≥30 patients, subgroup-only analysis would show a stronger signal than the pooled data
• No meta-analysis has stratified exclusively by BMI ≥30
• Estimated eligible studies: 6-12

Sub-gap C - Moderate ✅⚠️

• Both functional MAs (Choy 2021, Lauricella 2024) report LARS scores but with massive I²=97%
• Neither restricted analysis to measurements beyond 12 months post-stoma closure
• LARS improves significantly in the first 12 months after reversal - early measurements inflate apparent dysfunction rates
• A LARS-specific MA restricted to ≥12-month post-reversal follow-up would be more clinically meaningful
• Limitation: Only 5-7 studies likely report LARS at ≥12 months post-reversal, making pooling marginal

Bottom Line